Relative Bioavailability of Dabigatran After Single Oral Administration of Five Different Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Six-period, Five-sequence Crossover Study)

Trial Profile

Relative Bioavailability of Dabigatran After Single Oral Administration of Five Different Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Six-period, Five-sequence Crossover Study)

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Dabigatran etexilate
  • Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 14 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 31 May 2016 Planned End Date changed from 1 May 2016 to 1 Jun 2016.
    • 31 May 2016 Planned primary completion date changed from 1 May 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top